Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

2,413 questions · 2,602 findings · 93 reviews · Oral Health

No studies found 452 · 17.4%GRADE not reported 1,582 · 60.8%Very low 392 · 15.1%Low 122 · 4.7%Moderate 53 · 2%High 1 · 0%

Analgesic (any: NSAID, paracetamol, local anaesthetic or opioid) vs placebo or control

Quality of life or participant satisfaction · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)
1 finding from 1 review

Amifostine vs no treatment/placebo

Disease-free survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Amifostine showed no clear difference in disease-free survival compared with no treatment/placebo; GRADE not reported.

1 finding from 1 review

Amifostine vs no treatment/placebo

Quality of life · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Amifostine showed no clear difference in quality of life compared with no treatment/placebo; GRADE not reported.

1 finding from 1 review

Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo

Number of days unable to take medicine orally · Adults with cancer receiving treatment

The review found no eligible studies for this question.

1 finding from 1 review

Amifostine vs no treatment/placebo

Salivary flow rate (unstimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

It is very uncertain whether amifostine changes salivary flow rate (mg/5 min, unstimulated) compared with no treatment/placebo (very low certainty).

2 findings from 1 review

Amifostine vs no treatment/placebo

Progression‐free survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Amifostine showed no clear difference in progression-free survival compared with no treatment/placebo; GRADE not reported.

1 finding from 1 review

Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo

Adverse events · Adults with cancer receiving treatment
1 finding from 1 review

Granulocyte-colony stimulating factor (G-CSF; pegfilgrastim, single dose) vs Granulocyte-colony stimulating factor (G-CSF; filgrastim, multiple doses)

Oral mucositis (any severity) · Children receiving bone marrow/stem cell transplantation after conditioning therapy for mixed cancers

Granulocyte-colony stimulating factor (G-CSF; pegfilgrastim, single… showed no clear difference in oral mucositis (any severity) compared with granulocyte-colony stimulating factor (G-CSF; filgrastim, multiple…; GRADE not reported.

1 finding from 1 review

Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo

Salivary flow rate · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

The review found no eligible studies for this question.

1 finding from 1 review

Epidermal growth factor (EGF), oral spray vs placebo

Oral mucositis (moderate to severe) · Adults with cancer receiving treatment

Epidermal growth factor (EGF), oral spray showed no clear difference in oral mucositis (moderate to severe) compared with placebo; GRADE not reported.

2 findings from 1 review

Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs Chlorhexidine mouthwash

Oral mucositis (any severity) · Children with acute lymphoblastic leukaemia receiving chemotherapy alone

Keratinocyte growth factor (KGF), intravenous led to lower oral mucositis (any severity) compared with chlorhexidine mouthwash; GRADE not reported.

1 finding from 1 review

Amifostine vs no treatment/placebo

Dysgeusia (grade >= 2, 0-4 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Amifostine led to lower dysgeusia (grade >= 2, 0-4 scale) compared with no treatment/placebo; GRADE not reported.

1 finding from 1 review

Ibuprofen taken pre-emptively (about 1 hour before treatment) vs Ibuprofen taken post-treatment

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)

It is very uncertain whether ibuprofen taken pre-emptively (about 1 hour before treatment) changes pain intensity (VAS 0-100 mm) compared with ibuprofen taken post-treatment (very low certainty).

3 findings from 1 review

Zinc supplements vs Acupuncture

Outcome not reported · Patients with taste disturbances (dysgeusia/hypogeusia; idiopathic, zinc-deficient, or secondary to chronic renal failure)

The review found no eligible studies for this question.

1 finding from 1 review
  • Interventions for managing taste disturbances 2017 · Cochrane All outcomes
    Authors' conclusions: We were unable to draw any conclusions regarding the superiority of zinc supplements or acupuncture as none of the trials compared these interventions.
    0 studies
    No studies found

Granulocyte-colony stimulating factor (G-CSF; pegfilgrastim, single dose) vs Granulocyte-colony stimulating factor (G-CSF; filgrastim, multiple doses)

Normalcy of diet (total parenteral nutrition) · Children receiving bone marrow/stem cell transplantation after conditioning therapy for mixed cancers

Granulocyte-colony stimulating factor (G-CSF; pegfilgrastim, single… showed no clear difference in normalcy of diet (total parenteral nutrition) compared with granulocyte-colony stimulating factor (G-CSF; filgrastim, multiple…; GRADE not reported.

1 finding from 1 review

Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo

Overall survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Palifermin showed no clear difference in overall survival compared with placebo (moderate certainty).

1 finding from 1 review